{"success":true,"data":{"pressRelease":{"id":"101612","rtpr_id":"nGNX8DvbyH","ticker":"PODD","exchange":"NASDAQ","all_tickers":["PODD"],"title":"PODD Court Deadline: Insulet Investor Deadline in Securities Fraud Class Action is August 31 – Contact BFA Law if You Lost Money","author":"Globe Newswire","published_at":"2026-07-29T10:18:00.465Z","article_body":"NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law\nfirm Bleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=SGtLjdi5wlqz5jTg_QJro3D1yQjcRZfyZEe8xnc4wCSCjqz7NEcwz_0M-lexAh_dALOXoeKSziF3i43FZrUNJ4i8zELrnm2-4YVENVb6gtAVK-tKtOQ2asTlm_gqhlqqAEEZMn-f5x5b7w-SK6BqhbPQuh4ay6sPXhRkjHAT5Dk=)\nannounces that a class action lawsuit has been filed against Insulet\nCorporation (NASDAQ:PODD) and certain of the Company’s senior executives for\nsecurities fraud after its significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in Insulet, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit.\n\nKey Details of the Insulet ($PODD) Class Action:\n* Lead Plaintiff Deadline: August 31, 2026\n* Alleged Misconduct: Securities fraud relating to the safety of Insulet’s\nOmnipod products\n* Largest Alleged Stock Drop: March 12, 2026 – 6.88% Stock Drop\n* Court: U.S. District Court for the District of Massachusetts\n* Take Action: Contact BFA Law\n(https://www.bfalaw.com/cases/insulet-class-action-lawsuit) to discuss your\nrights\nInsulet investors have until August 31, 2026 to ask the Court to be appointed\nto lead the case. The complaint asserts securities fraud claims under Sections\n10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors\nin Insulet securities. The class action is pending in the U.S. District Court\nfor the District of Massachusetts. It is captioned Hu v. Insulet Corporation\net al., No. 26-cv-13062.\n\nWhy is Insulet Being Sued for Securities Fraud?\n\nInsulet is primarily engaged in the development, manufacture, and sale of\ninsulin delivery systems for people with insulin-dependent diabetes through\nits Omnipod platform. The Omnipod platform includes: the Omnipod® 5\nAutomated Insulin Delivery System (“Omnipod 5”), the Omnipod\nDASH® Insulin Management System (“Omnipod DASH”), and the Omnipod\nInsulin Management System (“Omnipod Eros”).\n\nThroughout the relevant period, Insulet misrepresented the safety of its\nOmnipod products as well as its ability to efficiently produce “medical\ngrade quality at consumer electronic scale.” In reality, certain of\nInsulet’s products suffered from undisclosed manufacturing defects that put\npatient safety at risk.\n\nWhy did Insulet’s Stock Drop?\n\nOn March 12, 2026, Insulet disclosed that a manufacturing issue with its\nOmnipod® 5 Pods caused a “tear in the internal tubing that delivers\ninsulin” resulting in insulin being released inside the Pod “instead of\nbeing fully infused into the body as intended.” Accordingly, Insulet\n“initiated a voluntary Medical Device Correction for specific lots of\nOmnipod® 5 Pods.”\n\nThis news caused the price of Insulet stock to drop $16.23 per share, or\n6.88%, from a closing price of $236.07 per share on March 12, 2026, to $219.84\nper share on March 13, 2026.\n\nOn May 26, 2026, Insulet announced another voluntary Medical Device Correction\ndue to a manufacturing issue, this time to its Omnipod 5, Omnipod DASH, and\nOmnipod Eros systems. It again indicated that the manufacturing issue resulted\nin a tear in the tubing which “could result in insulin under-delivery.”\n\nThis news caused the price of Insulet stock to drop $7.79 per share, or 5.07%,\nfrom a closing price of $218.11 per share on May 26, 2026, to $146.01 per\nshare on May 27, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Insulet, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.”  One testimonial described the firm\nas “nimble and entrepreneurial,” with a “relentless focus on adding\nvalue for clients.”\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8DvbyH","title":"PODD Court Deadline: Insulet Investor Deadline in Securities Fraud Class Action is August 31 – Contact BFA Law if You Lost Money","author":"Globe Newswire","ticker":"PODD","created":"2026-07-29T10:18:00.465Z","tickers":["PODD"],"exchange":"NASDAQ","article_body":"NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law\nfirm Bleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=SGtLjdi5wlqz5jTg_QJro3D1yQjcRZfyZEe8xnc4wCSCjqz7NEcwz_0M-lexAh_dALOXoeKSziF3i43FZrUNJ4i8zELrnm2-4YVENVb6gtAVK-tKtOQ2asTlm_gqhlqqAEEZMn-f5x5b7w-SK6BqhbPQuh4ay6sPXhRkjHAT5Dk=)\nannounces that a class action lawsuit has been filed against Insulet\nCorporation (NASDAQ:PODD) and certain of the Company’s senior executives for\nsecurities fraud after its significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in Insulet, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit.\n\nKey Details of the Insulet ($PODD) Class Action:\n* Lead Plaintiff Deadline: August 31, 2026\n* Alleged Misconduct: Securities fraud relating to the safety of Insulet’s\nOmnipod products\n* Largest Alleged Stock Drop: March 12, 2026 – 6.88% Stock Drop\n* Court: U.S. District Court for the District of Massachusetts\n* Take Action: Contact BFA Law\n(https://www.bfalaw.com/cases/insulet-class-action-lawsuit) to discuss your\nrights\nInsulet investors have until August 31, 2026 to ask the Court to be appointed\nto lead the case. The complaint asserts securities fraud claims under Sections\n10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors\nin Insulet securities. The class action is pending in the U.S. District Court\nfor the District of Massachusetts. It is captioned Hu v. Insulet Corporation\net al., No. 26-cv-13062.\n\nWhy is Insulet Being Sued for Securities Fraud?\n\nInsulet is primarily engaged in the development, manufacture, and sale of\ninsulin delivery systems for people with insulin-dependent diabetes through\nits Omnipod platform. The Omnipod platform includes: the Omnipod® 5\nAutomated Insulin Delivery System (“Omnipod 5”), the Omnipod\nDASH® Insulin Management System (“Omnipod DASH”), and the Omnipod\nInsulin Management System (“Omnipod Eros”).\n\nThroughout the relevant period, Insulet misrepresented the safety of its\nOmnipod products as well as its ability to efficiently produce “medical\ngrade quality at consumer electronic scale.” In reality, certain of\nInsulet’s products suffered from undisclosed manufacturing defects that put\npatient safety at risk.\n\nWhy did Insulet’s Stock Drop?\n\nOn March 12, 2026, Insulet disclosed that a manufacturing issue with its\nOmnipod® 5 Pods caused a “tear in the internal tubing that delivers\ninsulin” resulting in insulin being released inside the Pod “instead of\nbeing fully infused into the body as intended.” Accordingly, Insulet\n“initiated a voluntary Medical Device Correction for specific lots of\nOmnipod® 5 Pods.”\n\nThis news caused the price of Insulet stock to drop $16.23 per share, or\n6.88%, from a closing price of $236.07 per share on March 12, 2026, to $219.84\nper share on March 13, 2026.\n\nOn May 26, 2026, Insulet announced another voluntary Medical Device Correction\ndue to a manufacturing issue, this time to its Omnipod 5, Omnipod DASH, and\nOmnipod Eros systems. It again indicated that the manufacturing issue resulted\nin a tear in the tubing which “could result in insulin under-delivery.”\n\nThis news caused the price of Insulet stock to drop $7.79 per share, or 5.07%,\nfrom a closing price of $218.11 per share on May 26, 2026, to $146.01 per\nshare on May 27, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Insulet, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.”  One testimonial described the firm\nas “nimble and entrepreneurial,” with a “relentless focus on adding\nvalue for clients.”\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/insulet-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-29T10:18:00.604212244Z","server_sent_at_ms":1785320280604},"received_at":"2026-07-29T10:18:00.654Z","source_url":null},"analysis":{"id":"90636","press_release_id":"101612","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bleichmar Fonti & Auld LLP announced a class action lawsuit against Insulet Corporation regarding alleged securities fraud tied to the safety of its Omnipod products.\n\nThe firm cites stock declines in March and May 2026 following Insulet's disclosures of manufacturing defects that could lead to insulin under-delivery.\n\nInvestors have until August 31, 2026 to seek appointment as lead plaintiff, with representation offered on a contingency fee basis.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":null,"quotedText":"All representation is on a contingency fee basis; there is no cost to you.","namedEntities":{"people":[{"name":"Adam McCall","role":"Contact"}],"products":["Omnipod 5","Omnipod DASH","Omnipod Eros"],"companies":[{"name":"Insulet Corporation","ticker":"PODD"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"Tesla, Inc.","ticker":"TSLA","relationship":"mentioned"},{"name":"Teva Pharmaceutical Ind. Ltd.","ticker":"TEVA","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$16.23","context":"March 12, 2026 stock drop per share"},{"amount":"$236.07","context":"March 12, 2026 closing price"},{"amount":"$219.84","context":"March 13, 2026 closing price"},{"amount":"$7.79","context":"May 26, 2026 stock drop per share"},{"amount":"$218.11","context":"May 26, 2026 closing price"},{"amount":"$146.01","context":"May 27, 2026 closing price"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bleichmar Fonti & Auld LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[{"ticker":"TSLA","relevance":"mentioned"},{"ticker":"TEVA","relevance":"mentioned"}],"primary":"PODD"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bleichmar Fonti & Auld LLP announced a class action lawsuit against Insulet Corporation regarding alleged securities fraud tied to the safety of its Omnipod products.\n\nThe firm cites stock declines in March and May 2026 following Insulet's disclosures of manufacturing defects that could lead to insulin under-delivery.\n\nInvestors have until August 31, 2026 to seek appointment as lead plaintiff, with representation offered on a contingency fee basis.","key_figures":null,"named_entities":{"people":[{"name":"Adam McCall","role":"Contact"}],"products":["Omnipod 5","Omnipod DASH","Omnipod Eros"],"companies":[{"name":"Insulet Corporation","ticker":"PODD"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"Tesla, Inc.","ticker":"TSLA","relationship":"mentioned"},{"name":"Teva Pharmaceutical Ind. Ltd.","ticker":"TEVA","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$16.23","context":"March 12, 2026 stock drop per share"},{"amount":"$236.07","context":"March 12, 2026 closing price"},{"amount":"$219.84","context":"March 13, 2026 closing price"},{"amount":"$7.79","context":"May 26, 2026 stock drop per share"},{"amount":"$218.11","context":"May 26, 2026 closing price"},{"amount":"$146.01","context":"May 27, 2026 closing price"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-29T11:09:02.439Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":384752,"modelName":"glm-4.7"}}